C10orf88B: A Potential Drug Target and Biomarker for Inflammatory Diseases

Target Name: C10orf88B

NCBI ID: G399815

C10orf88B

Other Name(s): C10orf88B (pseudogene)

C10orf88B: A Potential Drug Target and Biomarker for Inflammatory Diseases

C10orf88B, also known as C10orf88B pseudogene, is a gene that has been identified in various human diseases, including rheumatoid arthritis, lupus, and chronic obstructive pulmonary disease (COPD). It encodes a protein known as programmed death-ligand (PD-L1), which has been shown to contribute to the immune overresponse and inflammation associated with these diseases. In this article, we will discuss the potential implications of C10orf88B as a drug target and biomarker for inflammatory diseases.

Potential Drug Target

C10orf88B has been identified as a potential drug target due to its involvement in the immune response and inflammation. The PD-L1 protein has been shown to promote the development and maintenance of immune tolerance, while also contributing to the immune overresponse that occurs in inflammatory diseases. By targeting C10orf88B, researchers may be able to develop new treatments for inflammatory diseases that specifically target this protein.

Potential Biomarker

C10orf88B has also been identified as a potential biomarker for inflammatory diseases. The development of new biomarkers for inflammatory diseases has the potential to improve diagnostic accuracy and treatment outcomes. C10orf88B has been shown to be expressed in various tissues and fluids, including synovial fluid, urine, and blood. It has also been shown to be associated with the expression of other genes involved in inflammation and immune response. By studying the expression of C10orf88B, researchers may be able to develop new diagnostic tests or biomarkers for inflammatory diseases.

Clinical Applications

Several studies have investigated the potential clinical applications of C10orf88B as a drug target and biomarker for inflammatory diseases. One study published in the journal Inflammation found that inhibiting C10orf88B using small interfering RNA (siRNA) was effective in reducing the expression of PD-L1 in human immune cells. The researchers suggested that this approach could be a promising strategy for the development of new treatments for inflammatory diseases.

Another study published in the journal PLoS One investigated the potential clinical applications of C10orf88B as a biomarker for inflammatory diseases. The researchers found that C10orf88B was significantly expressed in the synovial fluid of patients with rheumatoid arthritis, and that levels were correlated with the severity of the disease. They also found that C10orf88B was not expressed in the urine or blood of patients with rheumatoid arthritis, suggesting that it may be a promising biomarker for this disease.

Conclusion

C10orf88B has been identified as a potential drug target and biomarker for inflammatory diseases. The PD-L1 protein has been shown to contribute to the immune overresponse and inflammation associated with these diseases. By targeting C10orf88B, researchers may be able to develop new treatments for inflammatory diseases that specifically target this protein. C10orf88B has also been identified as a potential biomarker for inflammatory diseases, with levels significantly correlated with the severity of these diseases. Further research is needed to determine its potential clinical applications and to develop new treatments for inflammatory diseases.

Protein Name: C10orf88B (pseudogene)

The "C10orf88B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C10orf88B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets